Alkermes (ALKS) Treasury Shares (2011 - 2026)
Alkermes' (ALKS) quarterly Treasury Shares came in at $501.4 million in Q1 2026, up 11.92% year-on-year from $448.0 million in Q1 2025, and up 11.36% on a QoQ basis from $450.3 million in Q4 2025.
Alkermes (ALKS) Treasury Shares (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Treasury Shares data on file, last reported at $501.4 million in Q1 2026.
- On a quarterly basis, Treasury Shares rose 11.92% year-over-year to $501.4 million in Q1 2026; TTM through Mar 2026 was $501.4 million, a 11.92% increase from a year earlier, with the FY2025 full-year figure at $450.3 million, up 7.4% from the prior year.
- Treasury Shares for Q1 2026 stood at $501.4 million, up from $450.3 million in the prior quarter.
- Over the last five years, Treasury Shares for ALKS reached as high as $17.1 million in Q1 2026 and fell as low as -$15.4 million in Q2 2025.
- Historically, Treasury Shares has averaged -$497610.0 across 5 years, with a median of $4.5 million in 2022.
- Across the five-year window, Treasury Shares soared 124.09% in 2024 and climbed 7.4% in 2025, its largest moves.
- Year by year, Treasury Shares stood at $160.9 million in 2022, then increased by 17.7% to $189.3 million in 2023, then soared by 121.43% to $419.3 million in 2024, then climbed by 7.4% to $450.3 million in 2025, then climbed by 11.36% to $501.4 million in 2026.
- Per Business Quant data, the three most recent Treasury Shares figures were $501.4 million in Q1 2026, $450.3 million in Q4 2025, and $450.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 62.52 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 107.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.29 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 313.27 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.44 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 501.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 501.43 Mn |
| Mar 31, 2026 | 501.43 Mn |
| Mar 31, 2026 | 17.13 Mn |
| Mar 31, 2026 | 17.13 Mn |
| Dec 31, 2025 | 15.40 Mn |
| Dec 31, 2025 | 450.29 Mn |
| Dec 31, 2025 | 15.40 Mn |
| Dec 31, 2025 | 450.29 Mn |
| Sep 30, 2025 | 450.02 Mn |
| Sep 30, 2025 | 15.40 Mn |
| Sep 30, 2025 | 15.40 Mn |
| Sep 30, 2025 | 450.02 Mn |
| Jun 30, 2025 | -15.38 Mn |
| Jun 30, 2025 | 449.71 Mn |
| Jun 30, 2025 | 449.71 Mn |
| Jun 30, 2025 | -15.38 Mn |
| Mar 31, 2025 | 448.04 Mn |
| Mar 31, 2025 | -15.33 Mn |
| Mar 31, 2025 | -15.33 Mn |
| Mar 31, 2025 | 448.04 Mn |